When is MOH's next earnings date?

Based on SEC filing cadence, Molina Healthcare Inc (MOH)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is MOH stock expected to move on earnings?

Volatility modeling currently projects a ±9.3% event move for MOH, spanning a range between $189.06 and $227.84.

Stock Ratings / Health Care / MOH / earnings

CAI (73) HSIC (58) OSCR (53) GRAL (54) ⌘ Pro Terminal →

Molina Healthcare Inc (MOH) Next Earnings Date & Expected ±9.3% Move

$208.45 +1.79% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $208.73

Molina Healthcare Inc (MOH) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $10.69B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MOH Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MOH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Molina Healthcare Inc (NYSE: MOH) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $208.45 (+1.79% 1D, market cap $10.69B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, MOH ranks #187 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MOH compare to CAI and HSIC in the Health Care sector?

▼

Within the Health Care sector (Medical Specialities), MOH carries a Roarable D+ (57/100 RQD), trailing P/E of 22.0x, gross margin of 13.1%, and ROIC of 17.2%. By comparison, CAI (Caris Life Sciences Inc.) holds a B grade (73/100 RQD, P/E N/A, ROIC 4.4%, cap $9.70B) and HSIC (Henry Schein Inc.) posts a D+ grade (58/100 RQD, P/E 23.0x, ROIC 11.2%, cap $9.46B). Among the 5-stock peer group, MOH leads on earnings multiple (22.0x) while MOH leads on capital efficiency (17.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MOH?

▼

Per MOH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001179929), Molina Healthcare Inc generated $45.43B in revenue (+11.7% YoY), $472.0M in net income, and -$636.0M in free cash flow against $15.56B in total assets and $3.77B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $208.72 (+0.13%)🧬 Disciplined Float (+0.80% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MOH)Realized 20D OHLCV Swing Band: ±9.3%

Deterministic 5-Pillar Attribution (57/100 Composite)

🔍 WHY MOH SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (25% of score)

20D Institutional Volume Accumulation (±9.3% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (25% of score)

Altman Z-Score 4.34 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (+0.80% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$209.19+2.7% Next Q

Q2 (-2Q)

Grade C+$214.90-7.8% Next Q

Q3 (-1Q)

Grade C$198.10+5.2% Next Q

Current

Grade D+$208.45-0.2% Hist 90D α

Trajectory: C+ (65) → D+ (57)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the MOH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 57/100 (D+) score, MOH faces multiple-compression risk if 22.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($200.67) or 200D SMA ($185.03) invalidates the momentum regime and cuts Target Base ($207.51) toward Bear Floor ($161.86).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MOH• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MOH Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 57%NO 43%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±9.3% Swing Band

±$19.39 Expected Swing

MODEL EARNINGS SETUP GAUGE

MOH Quantitative Pre-Earnings Setup: 57/100

Trailing EPS: $9.04 • YoY Revenue Growth: 11.7%

Model Bullish Setup (57/100)Model Risk Weight (43/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$45.43B	$472.0M	-$636.0M	13.1%
FY 2024	2024-12-31	$40.65B	$1.18B	$544.0M	15.3%
FY 2023	2023-12-31	$34.07B	$1.09B	$128.8M	13.1%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MOH)

✓Walkthrough of MOH's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MOH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.61%📐 HORIZONTAL RANGE

2026-11-03O $199.0H $208.5L $199.0C $208.5VOL 1.75M

RES: $228.1SUP: $174.1SMA50: $200.7SMA200: $185.0

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MOH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MOH Butterfly Map → + Track MOH →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

15.7%/yr Implied 5Y Growth

vs. +11.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MOH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MOH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MOH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MOH)

Health Care Rank #187 of 1015 ⚔️ CAI vs MOH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MOH vs. CAI, HSIC, OSCR, GRAL)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Molina Healthcare Inc (MOH) ranks #187 by composite RQD confidence (57/100, grade D+) and #100 by equity capitalization ($10.69B). Within this direct 5-issuer industry benchmark cohort, MOH leads on earnings valuation at 22.0x trailing P/E, while MOH leads on capital efficiency and profitability with 17.2% ROIC and 13.1% gross margin. CAI currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with MOH at 57/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MOH ACTIVE Molina Healthcare Inc	D+	57/100	22.0x	13.1%	17.2%	+1.79%	$10.69B	Benchmark Subject
CAI Caris Life Sciences Inc.	B	73/100	—	—	4.4%	-6.50%	$9.70B	/cai-vs-moh →
HSIC Henry Schein Inc.	D+	58/100	23.0x	31.1%	11.2%	+2.05%	$9.46B	/hsic-vs-moh →
OSCR Oscar Health Inc.	D+	53/100	—	—	-35.0%	+2.07%	$9.37B	/oscr-vs-moh →
GRAL GRAIL Inc.	D+	54/100	—	—	-18.0%	-6.74%	$6.41B	/gral-vs-moh →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001179929 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Molina Healthcare Inc (MOH) reported GAAP revenue of $45.43B (+11.7% vs. FY2024 revenue of $40.65B , and +33.3% cumulative change since FY2023) , GAAP net income of $472.0M, operating cash flow of -$535.0M, and free cash flow of -$636.0M (-216.9% YoY). On the balance sheet, MOH closed FY2025 with $15.56B in total assets against $3.77B in total debt (Altman Z-Score: 4.34, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$45.43B	$472.0M	-$535.0M	-$636.0M	$15.56B	$3.77B
FY2024 (FY)	2024-12-31	$40.65B	$1.18B	$644.0M	$544.0M	$15.63B	$2.92B
FY2023 (FY)	2023-12-31	$34.07B	$1.09B	$1.66B	$128.8M	$40.89B	$9.57B

3. MOH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MOH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MOH compare to CAI and HSIC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MOH?

Where is MOH trading relative to its 50-day, 200-day, and 52-week technical levels?

MOH last traded at $208.45 (+1.79% on volume of 1,269,556 shares), positioning the stock +3.88% above its 50-day simple moving average ($200.67) and +12.66% above its 200-day simple moving average ($185.03). Across its 52-week range of $121.06 to $244.89, MOH sits at the 70.6% percentile with a 14-day RSI of 52.0 (NEUTRAL RANGE) and an implied next-earnings move of ±9.3% ($189.06 to $227.84).

Direct Sub-Reports: MOH RQD Cockpit MOH 12M Forecast MOH Earnings & Move MOH Dividends & DRIP MOH Insiders & 13F MOH Whale Options MOH Profit Sankey MOH News & Why

ROARABLE RATING BRIEF • RQD 57/100 (D+) ✓ SEC XBRL & RQD VERIFIED

MOH — Molina Healthcare Inc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Molina Healthcare Inc (MOH) earns a live Roarable RQD composite score of 57/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $208.45 (+1.79% 1D, market capitalization $10.69B).

Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of 17.2%, gross margin of 13.1%, operating margin of 1.7%, and free cash flow yield of -6.12%.
Whale 13F & Options Flow (14/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (14/20): Incorporates a 0.94x equity beta, Altman Z-Score of 4.34, Piotroski F-Score of 4/9, and Debt/Equity of 0.93x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Molina Healthcare Inc (MOH) is a NYSE-listed operating company in the Medical Specialities industry (Health Care sector) with an equity market capitalization of $10.69B. The business operates with a gross margin of 13.1%, an operating margin of 1.7%, and a return on invested capital (ROIC) of 17.2% (free cash flow yield of -6.12%). Within the Medical Specialities peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Molina Healthcare Inc (MOH) reported $45.43B in annual revenue (up from $40.65B in FY2024, +11.7% YoY) and $472.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($34.07B revenue, $1.09B net income) through FY2025, MOH scaled operating cash flow to -$535.0M and free cash flow to -$636.0M, backed by $15.56B in total assets against $3.77B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D+ • RQD 57/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -6.12% and institutional whale pillar of 14/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $121.06 – $244.89 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 22.0x trailing P/E and 11.4x EV/EBITDA against 1.7% operating margins and a 0.94x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical Specialities (Health Care), MOH carries a macro regime beta of 0.94 and gross margin of 13.1%.

Key Question #1: Can MOH sustain or expand its 1.7% operating margin and 17.2% ROIC against Medical Specialities peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $45.43B and free cash flow of -$636.0M, how will capital allocation balance growth reinvestment against $3.77B in total debt?
Key Question #3: How sensitive is MOH's 20.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.94x)?

MOH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Molina Healthcare Inc (MOH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MOH Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 23h ago

Molina Healthcare (MOH) Stock May Trade At A Discount Despite Reaffirmed 2026 Guidance

Yahoo Finance report covering Molina Healthcare Inc (MOH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Forbes • 1d ago

Molina Healthcare

Forbes report covering Molina Healthcare Inc (MOH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Molina Healthcare: Paying 21x For A Recovery That Hasn't Happened Yet

Seeking Alpha report covering Molina Healthcare Inc (MOH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Molina Healthcare’s (NYSE:MOH) Q3 2026 sales top estimates

TradingView report covering Molina Healthcare Inc (MOH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Molina Healthcare (MOH) Stock May Look Reasonable On Its Sales Base

Simply Wall St report covering Molina Healthcare Inc (MOH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

Molina Healthcare (MOH) Stock Drops After Q3 Results Expose Margin Squeeze

Yahoo Finance report covering Molina Healthcare Inc (MOH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH GuruFocus • 1d ago

Molina Healthcare Inc (MOH) Shares Fall 3.5% -- What GF Score of 80 Tells Investors

GuruFocus report covering Molina Healthcare Inc (MOH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

Molina Healthcare (MOH) Shares Dip After Q3 Beat Despite Strong Revenue Growth

GuruFocus report covering Molina Healthcare Inc (MOH) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MOH Bull vs. Bear Conversation Board — What's Your Call at $208.45?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MOH 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $249.83 (+22.0%)

📌 Pinned Debate

Forensic balance sheet scores 14 of 20 with Altman Z 4.34 and ROIC 17.2%, indicating financial strength beneath weak near-term cash flo

Picked up a starter position in MOH in my $100K Virtual Cash book at $204.78. Forensic balance sheet scores 14 of 20 with Altman Z 4.34 and ROIC 17.2%, indicating financial strength beneath weak near-term cash flow.. Trading inside a $121.06–$244.89 52-week range with -6.12% FCF yield gives solid downside support if Medical Specialities multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@MultipleCompression Fair point on 22.0x trailing P/E, but you're ignoring the forward operating leverage in Medical Specialities. If gross margin (13.1%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $176.11 (-14.0%)

Spot @ $204.78

FY 2025 free cash flow of -$636.0M, FCF yield of -6.12%, and a 1.7% operating margin leave limited cushion against the 22x trailing P/E

FY 2025 free cash flow of -$636.0M, FCF yield of -6.12%, and a 1.7% operating margin leave limited cushion against the 22x trailing P/E.. Look at the math on MOH: paying 22.0x trailing P/E for 17.2% ROIC and 1.7% operating margins leaves zero margin of safety if Medical Specialities demand softens. I'd wait for a retest of $180.21 before getting long.